Where can I listen to this podcast?

This podcast is available on 7 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

No, this podcast does not typically feature guests.

Inside 340B Report

Claim This Podcast

by 340B Report

5.0(4 reviews)

45 episodes

Updated Weekly

Accepts GuestsHas SponsorsLocation 🇺🇸

Podcast Authority

Beta

PoorBased on show quality, social media presence, reviews, charts, and more

Quality53

Social0

YouTube0

Engagement32

Learn more

Podcast Overview

Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report's newsroom for a candid, insider's perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.

Language

🇺🇲

Publishing Since

9/3/2024

Visit Website View on Apple Podcasts RSS Feed

🇺🇸 Charts #3

Outreach generated

Apple 142

Spotify 827

Instant mention tracking

Perfect fit!

Unlock The Full Podcast Authority Score Report

See how your podcast performs across key metrics

Podcast Authority

Beta

PoorBased on show quality, social media presence, reviews, charts, and more

Quality53

Social0

YouTube0

Engagement32

Learn more

Excellent Areas

Good Performance

Growth Opportunities

excellent

Episode Length

31 minutes

Performing excellently!

good

Publishing Consistency

Every 15 days

Recommendations available

Unlock the full report to see detailed tips

poor

Episode Thumbnails

Recommendations available

Unlock the full report to see detailed tips

+16 More Metrics

Unlock comprehensive insights including:

• YouTube presence analysis
• Social media reach metrics
• RSS compliance scoring
• Podcast 2.0 features
• Technical standards

What's Included in Your Full Report

Detailed Analytics

Complete breakdown of all 19 authority metrics
Personalized recommendations for each metric
Industry benchmarks and comparisons
Technical RSS feed analysis and compliance scoring

Growth Strategies

Step-by-step action plans for improvement
Quick wins to boost your score immediately
Pro tips from successful podcasters

Get your free podcast insights report

See how your show performs across every key metric

Instant delivery

No spam

Attract Better Guests

High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.

Secure Sponsorships

Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.

Grow Your Audience

Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.

1 verified contact email on file for Inside 340B Report

Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.

See contact details

Recent Episodes

July 24, 2026

Episode 44: Arkansas Targets Drugmakers, 340B Lobbying Holds Steady, Rebate Model Marches On

<span id= "docs-internal-guid-29024106-7fff-ad91-791c-c9ab65a140d2" style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> In this episode, 340B Report Editor-in-Chief Will Newton joins Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: a new Arkansas state lawsuit against 13 drugmakers and Second Sight Solutions; a key U.S. senator's recent comments on the program and new federal 340B lobbying data; and an update on the Health Resources and Services Administration's (HRSA) latest efforts to implement a controversial 340B rebate pilot. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Key Topics Covered: <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Arkansas Files Suit <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Will breaks down Arkansas Attorney General Tim Griffin's (R) new lawsuit against 13 drugmakers and drug industry vendor Second Sight Solutions for allegedly violating the state's 340B access law. He details Griffin's press conference announcing the lawsuit, where he predicted it would become a "billion-dollar case" while surrounded by state 340B providers and advocates. Luke notes that AstraZeneca exempted Louisiana covered entities from its contract pharmacy restrictions after a court declined it and other drugmakers' request for a rehearing in a case relating to that state's contract pharmacy access law. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Meanwhile, On Capitol Hill <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Shannon discusses U.S. Sen. Bill Cassidy's (R-La.) latest comments on the 340B program during a recent Senate Health, Education, Labor and Pensions (HELP) Committee markup. Cassidy, a vocal 340B critic who chairs the HELP Committee, cautioned that an amended version of legislation to cap monthly insulin costs at $35 and create a pilot program to help states provide affordable insulin to uninsured patients could give "cover for 340B entities which are not using the [340B] program" the way Congress intended. Shannon also breaks down the latest 340B federal lobbying data, including what groups spent the most during the second quarter of 2026. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Rebate Model Update <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Will offers that it seems like a matter of when, not if, HRSA will release its new 340B rebate pilot notice. He notes that White House regulators recently held their last scheduled meeting on the proposal, which remains under regulatory review. Will also explains that providers continue to oppose 340B rebates and dispute HRSA's assessment of its burden. He then breaks down a recent federal appeals court decision that upheld HRSA's authority over 340B rebates, while rejecting drugmakers' claims that they could implement rebates without prior approval. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Subscribe & Stay Updated <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> How to Follow Us and Learn More About This Episode's Sponsor <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Stay tuned for more episodes every other week! <span style= "font-size: 12pt; font-family: REM,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> 🎧<span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: #ffffff; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> This episode is brought to you by one of our great Ultra Diamond sponsors, <a style="text-decoration: none;" href= "https://www.visante.com/"><span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #1155cc; background-color: #ffffff; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;"> Visante</a><span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: #ffffff; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">. Visante partners with health systems to deliver confidence in 340B—through deep experience, rigorous compliance and relentless focus on program compliance. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> We are very grateful to Visante for its sponsorship. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Subscribe to 340B Report with a Special Discount <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a style= "text-decoration: none;" href= "https://340breport.com/subscribe/"><span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #0563c1; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;"> subscribe now</a> <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a style="text-decoration: none;" href= "https://subscribers.340breport.com/checkout?plan=59319"><span style="font-size: 12pt; font-family: Calibri,sans-serif; color: #0563c1; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;"> free trial</a><span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">.

July 10, 2026

Episode 43: Congress Takes Up 340B, CMS Proposes Big Part B Cuts and Lilly Faces Lawsuit

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: a trio of congressional 340B proposals; potential steep Medicare Part B cuts for 340B hospitals; and a new provider lawsuit challenging Eli Lilly's move to cut off 340B pricing. Key Topics Covered: Three Major 340B Legislative Proposals Shannon, Luke and Ted discuss three new 340B-related proposals in Congress. Shannon breaks down U.S. Sen. Bill Cassidy's (R-La.) recently unveiled 340B discussion draft, which proposes several changes to the drug discount program that largely drew pushback from 340B provider advocates and support from the drug industry. Cassidy, who chairs the Senate Health, Education, Labor and Pensions (HELP) Committee, will leave Congress at the end of 2026. Shannon also discusses the U.S. House Ways & Means Committee's recent markup of a bill that would require certain hospitals to report 340B-related information on federal tax forms. Luke discusses a new bipartisan House bill that would also make several changes to the 340B program, but received mixed reactions from stakeholders. Ted offers insight on the various proposals, including how stakeholders have reacted to them. CMS Eyes Steep Cuts for 340B Hospitals Will breaks down the Centers for Medicare & Medicaid Services' (CMS) proposal to cut Medicare Part B reimbursement for 340B hospitals by nearly 37%. He notes that CMS argues the effort will save taxpayers money, while hospitals contend it will undermine the 340B program's purpose of expanding access and services for vulnerable patients. Will also explains that CMS attempted to cut Part B reimbursement during the first Trump administration—before the U.S. Supreme Court unanimously overturned that effort on procedural grounds. Florida Hospital Sues Lilly Over 340B Data Reqs Will details a Florida teaching hospital's recent federal lawsuit challenging Lilly's move to cut off 340B pricing for failure to comply with the drugmaker's new 340B in-house pharmacy claims data requirements. He notes that more provider lawsuits are likely to follow, but explains that covered entities can face legal obstacles when attempting to directly sue drugmakers under 340B. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This episode is brought to you by one of our great Ultra Diamond sponsors, <a href= "https://www.proximityhealth.com/">Proximity</a>. Proximity is the 340B revenue operations platform built to bring control back to your program. Proximity unifies and normalizes TPA, pharmacy, EHR, wholesaler and payer data into a single system—so issues can be identified, corrected and resolved across the full claim lifecycle. To learn more, reach out to <a href= "mailto:hello@proximityhealth.com">hello@proximityhealth.com</a>. We are very grateful to Proximity for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a href="https://340breport.com/subscribe/">subscribe now</a> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a href= "https://subscribers.340breport.com/checkout?plan=59319"> free trial</a>.

June 19, 2026

Episode 42: Lilly Move and What to Expect Next, State Activity and Premier Lawsuit Implications

<span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: Eli Lilly's move to cut off 340B pricing for certain hospitals; the Health Resources and Services Administration's (HRSA) efforts to implement another rebate pilot, the government's decision to not appeal a key hospital purchasing policy court ruling and recent 340B activity in the states. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Key Topics Covered: <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Lilly Cuts Off Non-Compliant Hospital 340B Pricing<span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Shannon and Ted discuss Lilly's decision to end 340B pricing for certain hospitals that failed to comply with its 340B in-house pharmacy claims data requirements and how hospital trade groups responded to that move. Shannon notes that while 340B Health and the American Hospital Association urged HRSA to step in, the agency said it was still determining its "next steps." Luke talks about possible actions states may take in response to Lilly's actions and other drugmakers' in-house claims data requirements. And Will notes that Vermont recently updated its state 340B law to protect covered entities in response to manufacturer in-house policies. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> HRSA Takes Another Step Towards Rebate Pilot <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Will breaks down new HRSA regulatory documents and what they mean about a potential future 340B rebate pilot. He notes that HRSA is attempting to avoid the missteps that led federal courts to block the agency's original rebate pilot from taking effect. Will also explains that providers have disputed HRSA's estimate on the administrative burden of a rebate pilot, quoting a former HRSA official who argued it was "mind-boggling" that the agency hadn't changed its assessment. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Key State and Court Actions <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Shannon breaks down HRSA's decision not to appeal a Washington, D.C. federal district court's ruling to strike down a controversial 13-year-old policy that restricted how certain 340B hospitals can purchase initial drug inventory. She notes that while hospitals celebrated the move and its implications, the agency could still pursue the issue through regulation—or more likely—federal guidance. Ted offers background on the group purchasing organization (GPO) prohibition and the significance of HRSA's ruling. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Will discusses a federal court ruling that allowed Washington state's 340B contract pharmacy access law to take effect this month. He also provides an update on Illinois' pair of 340B bills that are currently awaiting action from the state's governor. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> July Panel on Key 340B Developments <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Join Verity Solutions for a panel discussion just ahead of the 340B Coalition Summer Conference. The complimentary event will take place July 13 from 8 to 9:15 a.m. ET at the Gaylord National Resort in National Harbor, Maryland. The event is open to all and separate from the Coalition Conference, so you need to register in advance. Learn more and register <a style="text-decoration: none;" href= "https://340breport.com/340b-beyond-the-headlines-policy-compliance-and-legislative-impact-verity-sponcon/"> <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #1155cc; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;"> here</a><span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Subscribe & Stay Updated <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> How to Follow Us and Learn More About This Episode's Sponsor <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Stay tuned for more episodes every other week! <span style= "font-size: 12pt; font-family: REM,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> 🎧<span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Each episode is brought to you by one of our great Ultra Diamond sponsors, <a style="text-decoration: none;" href= "https://vytlone.com/the-strategic-dose-podcast/"><span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #1155cc; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;"> VytlOne</a><span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care and reinvest in communities. We are very grateful to VytlOne for its sponsorship. <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Subscribe to 340B Report with a Special Discount <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a style= "text-decoration: none;" href= "https://340breport.com/subscribe/"><span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #0563c1; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;"> subscribe now</a> <span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a style="text-decoration: none;" href= "https://subscribers.340breport.com/checkout?plan=59319"><span style="font-size: 12pt; font-family: Calibri,sans-serif; color: #0563c1; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;"> free trial</a><span style= "font-size: 12pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">.

45 total episodes available

Similar Podcasts

Discover related shows you might enjoy

340B Unscripted

SpendMend Pharmacy

340B 360

340B Report

340B Insight

340B Health

340Banter Podcast

FQHC 340B Compliance

Katy's 340B Compass: Compliance Made Clear

Virtue 340B

The Daily Punch

Punchbowl News

KFF Health News' 'What the Health?'

KFF Health News

Dare to Lead with Brené Brown

Vox Media Podcast Network

I Will Teach You To Be Rich

Ramit Sethi

POLITICO Playbook Daily Briefing

POLITICO

Mad Money w/ Jim Cramer

CNBC

Craig Groeschel Leadership Podcast

Life.Church

Up First

NPR

The Readout Loud

STAT

The Daily

The New York Times

Deep-dive analytics for Inside 340B Report

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is Inside 340B Report?: Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report's newsroom for a candid, insider's perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.
How often does this podcast release new episodes?: This podcast updates weekly.
Where can I listen to this podcast?: This podcast is available on 7 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Does this podcast accept guests?: No, this podcast does not typically feature guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.